(Total Views: 446)
Posted On: 01/28/2020 10:47:54 PM
Post# of 72440
Mo, your analysis is always very good and detailed. I think you are overestimating how much attention to detail many IPIX board regulars pay to this investment. I think your very firm grasp of both the scientific and financial sides of this coin is causing you to read malice into the words of a temporarily less-informed poster.
It is easy to see where BooDog's confusion came from with the first paragraph of the 1/24/20 PR. Yes, some of the miscreants elsewhere are intentionally saying it is a colonic now but that is another story. BooDog corrected himself quickly and I think he genuinely learned something about the trial. If they had slapped an "oral" between "release" and "tablets" I could see your point but it was worded oddly and I know I did a double-take on the phrasing when I first read it.
Quote:
WAKEFIELD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company completed dosing in the third and final cohort in the Phase 1 trial investigating the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.
It is easy to see where BooDog's confusion came from with the first paragraph of the 1/24/20 PR. Yes, some of the miscreants elsewhere are intentionally saying it is a colonic now but that is another story. BooDog corrected himself quickly and I think he genuinely learned something about the trial. If they had slapped an "oral" between "release" and "tablets" I could see your point but it was worded oddly and I know I did a double-take on the phrasing when I first read it.
(4)
(1)
Scroll down for more posts ▼